Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Adv Anat Pathol. 2017 Sep;24(5):259–267. doi: 10.1097/PAP.0000000000000158

Figure 4.

Figure 4

Model of GIST genomic progression. Primary KIT, PDGFRA or NF1 mutations represent the initiating oncogenic driver events in most GISTs and are followed by stepwise accumulation of chromosomal aberrations, harboring putative tumor suppressor genes, and cell cycle dysregulating events. Metastatic GISTs develop treatment resistance through evolving TKI-resistant subclones with additional secondary KIT or PDGFRA mutations.